(1R,5R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide

• ChemBase编号: 216
• 分子式: C20H30BrNO3
• 平均质量: 412.3611
• 单一同位素质量: 411.14090583
• SMILES: O(C1C[C@@H]2[N+]([C@H](CC2)C1)(C(C)C)C)C(=O)C(CO)c1ccccc1.[Br-]
• Canonical SMILES: OCC(c1ccccc1)C(=O)OC1C[C@H]2CC[C@H](C1)[N+]2(C)C(C)C.[Br-]
• InChI: InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17-,18?,19?,21?;/m1./s1
• InChIKey: LHLMOSXCXGLMMN-AUFQYUNVSA-M

名称和登记号

名称

• IUPAC标准名: (1R,5R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide
• IUPAC传统名: atrovent bromide
• 商标名: Aerovent; Apo-Ipravent; Apovent; Atronase; Atrovent; Atrovent Aerosol; Atrovent HFA; Atrovent Nasal; Bitrop; Disne-Asmol; Ipravent; Ipvent; Kendral-Ipratropium; Narilet; Rhinotrop; Rhinovent; Rinatec; Rinoberen; Rinovagos; Vagos; Aerodose
• 别名: Ipatropium Bromide; Ipratropium Bromide; N-Isopropylatropine; ipratropium; Ipratropium bromide

登记号

• CAS号: 60205-81-4
• PubChem SID: 160963679
• PubChem CID: 11553369

理论计算性质

JChem

• Acid pKa: 15.14574
• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): -1.8177127
• LogD (pH = 7.4): -1.8177124
• Log P: -1.8177127
• 摩尔折射率: 105.8974 cm^3
• 极化性: 37.49658 Å^3
• 极化表面积: 46.53 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.89
• LOG S: -5.48
• 溶解度: 1.22e-03 g/l

分子性质

理化性质

• 溶解度: Freely soluble

详细说明

DrugBank - DB00332

• Drug Groups: approved
• Description: A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]
• Indication: For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
• Pharmacology: Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
• Toxicity: LD₅₀=1001mg/kg (orally in mice)
• Affected Organisms: Humans and other mammals
• Biotransformation: Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; α-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH₃OH-group. These metabolites appear to be inactive.
• Absorption: Inhalation (local)-minimal; Nasal-rapid and minimal
• Half Life: 2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t_{1/2 α}) and terminal elimination-phase half-life (t_{1/2 β}) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.
• Protein Binding: Minimally (0 to 9% in vitro) bound to plasma albumin and α1-acid glycoproteins
• Elimination: Primarily eliminated renally via active secretion.
• Distribution: * 4.6 L/kg
• Clearance: * 2.3 L/min (total clearance of active ingredient)
• References: Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y: [Antiallergic asthma effect of ipatropium bromide (Sch 1000) in dogs (author's transl)] Nippon Yakurigaku Zasshi. 1977 Oct;73(7):785-91. [Pubmed] ; Abdine HH, Belala F, and Al-Badra AA. (2003). Ipratropium bromide: Methods of chemical and biochemical synthesis. In H.G. Brittain (Ed.). _Profiles of drug substances, excipients and related methodology_ (pp. 85-99). Amsterdam, Netherlands: Elsevier Academic Press.
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y: [Antiallergic asthma effect of ipatropium bromide (Sch 1000) in dogs (author's transl)] Nippon Yakurigaku Zasshi. 1977 Oct;73(7):785-91. PubmedAbdine HH, Belala F, and Al-Badra AA. (2003). Ipratropium bromide: Methods of chemical and biochemical synthesis. In H.G. Brittain (Ed.). _Profiles of drug substances, excipients and related methodology_ (pp. 85-99). Amsterdam, Netherlands: Elsevier Academic Press.